RxDoctor Payments Data

Amit Varma, MD

Advanced Heart Failure and Transplant Cardiology · Lancaster, PANPI 1477762425

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $17,275 of the $20,629 with a category attached, or 83.7%. Pfizer accounts for 82.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $9,360 and has fallen 98.8% since, to $108 in 2025.

$20,629in general payments, 2019–2025

Across 55 payments — averaging $375.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$17K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
  • Novartis$198
  • Abiomed$155
  • United Therapeutics Corporation$142
  • Akcea Therapeutics, Inc.$125
  • plus $333 from 5 others
$88,279in research payments, 2019–2025

Across 22 payments — averaging $4012.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • American Regent$46K
  • Medtronic$23K
  • Boehringer Ingelheim$17K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$3K

What the payments were for

  • Speaking & faculty fees$17,27584%
  • Travel & lodging$1,6968%
  • Food & beverage$1,6518%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,629 in reported general payments places this provider in the 70th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

See all advanced heart failure and transplant cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$150,988
Medicare patients
863
Services billed
1,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis116$2,528,765
EliquisApixaban91$101,291
EntrestoSacubitril/Valsartan64$77,172
JardianceEmpagliflozin46$56,701
FarxigaDapagliflozin Propanediol14$21,528
XareltoRivaroxaban20$21,265
Metoprolol Succinate301$4,900
Klor-ConPotassium Chloride11$2,443
Torsemide69$1,509
Potassium Chloride30$1,142
Furosemide156$844
Losartan Potassium93$834
Hydralazine Hcl51$560
Isosorbide Mononitrate ErIsosorbide Mononitrate34$512
Spironolactone77$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$17,092$2,630,056207 claims
NovartisEntresto$198$77,17264 claims
AstraZenecaFarxiga$21$21,52814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

Other advanced heart failure and transplant cardiology in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →